In January 2018, Russia imported 30.6 bln RUB worth of ready-made drugs (free circulation prices), which is in monetary terms 1.5% higher than that of January 2017, and 6.5 bln RUB worth of in-bulk drugs, which is 4.4% lower than that of January 2017. In physical terms, Russia imported 126.8 mln units of ready-made drugs, which is 0.2% higher than that of January 2017. As for MDU (minimum dosage units), Russia imported 2.8 bln MDUs of ready-made and in-bulk drugs. The dynamics of the in-bulk import are 58%, which contributed to the positive dynamics of the import if calculated in MDU (+4%). However, the import of ready-made drugs has fallen by 3.7% if calculated in MDU.

Valenta and Merck Group were among the leaders in the in-bulk import in January 2018. In physical terms, the import of Valenta in-bulk drugs has increased by nearly 60 times thanks to Trimedat. The import of Merck Group in-bulk drugs has increased by 35 times thanks to Concor and Glucophage.

The leader in the import of ready-made drugs is Gedeon Richter, with a 3.1 times growth, followed by Shreya Life Sciences, with a 2.2 times growth. Mydocalm and Airtal contributed to the progress of Gedeon Richter, while Suprima-LOR and Penzital contributed to Shreya Life Sciences.

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2017 – January 2018)